ENDRA Life Sciences (NDRA) Expected to Release Earnings on Thursday

ENDRA Life Sciences (NASDAQ:NDRA) is expected to be announcing its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to post earnings of ($0.84) per share and revenue of $0.10 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

ENDRA Life Sciences (NASDAQ:NDRA) last released its quarterly earnings data on Friday, May 15th. The company reported ($1.09) EPS for the quarter, beating the consensus estimate of ($1.23) by $0.14. On average, analysts expect ENDRA Life Sciences to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

ENDRA Life Sciences Price Performance

NASDAQ:NDRA opened at $4.54 on Thursday. The firm has a market capitalization of $5.77 million, a P/E ratio of -0.56 and a beta of -0.05. ENDRA Life Sciences has a 1-year low of $2.96 and a 1-year high of $9.85. The company’s fifty day moving average price is $4.93 and its 200-day moving average price is $4.60.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on NDRA. Weiss Ratings upgraded shares of ENDRA Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, July 31st. Ascendiant Capital Markets cut their price target on ENDRA Life Sciences from $27.00 to $25.00 and set a “buy” rating on the stock in a research report on Monday, June 1st. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $25.00.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.